Geron Advances Blood Cancer Treatment with Promising Results from GTB-3650 Immunotherapy Trials

GT Biopharma Advances Immunotherapy for Blood Cancers with GTB-3650

GT Biopharma, Inc. is making significant progress in the realm of cancer treatment through its innovative immunotherapy drug, GTB-3650. The company recently completes a safety review for Cohort 3 of its Phase 1 clinical trial, which focuses on patients suffering from relapsed or refractory blood cancers, particularly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This review confirms that the treatment exhibits no safety or tolerability issues, enabling GT Biopharma to advance to the next phase of the trial with confidence. In Cohort 4, patients will receive a dose of 10μg/kg/day, with screening for participants currently underway and dosing expected to commence soon.

The Phase 1 study has already treated six patients across the initial cohorts, all of whom demonstrate tolerability at increasing doses. The treatment regimen for GTB-3650 involves continuous infusions administered over two weeks, followed by a two-week rest period, allowing for a total treatment cycle of up to four months based on individual patient responses. Promising trends in immunological biomarkers observed in treated patients have led the company to believe that the upcoming dosing in Cohort 4 may represent a potential threshold for clinical efficacy. This advancement not only highlights the potential of GTB-3650 in combating some of the most challenging forms of blood cancer but also reflects a broader trend in the industry toward targeted therapies.

The recent FDA approval of the first once-daily menin inhibitor for relapsed NPM1-mutated AML underscores the increasing emphasis on targeted treatments in the oncology landscape. As GT Biopharma continues to develop its immunotherapy platform, the company is poised to contribute significantly to the fight against blood cancers. With a comprehensive update on its progress expected in the first quarter of 2026, GT Biopharma aims to solidify its position as a key player in advancing immunotherapeutic options for patients facing difficult cancer diagnoses.

In addition to these clinical advancements, the positive safety profile of GTB-3650 could have broader implications for the development of immunotherapies. As the company navigates the complexities of clinical trials, its findings may pave the way for similar treatments targeting other challenging malignancies. The growing recognition of immunotherapy’s potential in oncology is further supported by the ongoing research and development efforts across the industry, as companies seek to refine and expand treatment options for cancer patients worldwide.